絞り込み

16506

広告

Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation.

著者 Deitelzweig S , Luo X , Gupta K , Trocio J , Mardekian J , Curtice T , Lingohr-Smith M , Menges B , Lin J
J Manag Care Spec Pharm.2017 Nov ; 23(11):1191-1201.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (37view , 0users)

Full Text Sources

Miscellaneous

The clinical trial ARISTOTLE showed that apixaban was superior to warfarin in reducing the risks of stroke and bleeding among patients with nonvalvular atrial fibrillation (NVAF). Further study of the effect of apixaban versus warfarin use on health care resource utilization (HCRU) and associated costs in the real-world setting is warranted, especially among elderly patients who are at higher risk of stroke and bleeding.
PMID: 29083968 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード